Tyra Biosciences to Present at the Cantor Global Healthcare Conference

Tyra Biosciences (TYRA) will present at the Cantor Global Healthcare Conference 2026 in a virtual fireside chat and one-on-one investor meetings.

Rhea-AI Summary

Tyra Biosciences (TYRA) will present at the Cantor Global Healthcare Conference 2026 in a virtual fireside chat and one-on-one investor meetings.

The presentation is scheduled for Wednesday, September 9, 2026 at 1:00 PM ET, with the conference held in New York, NY. A live webcast and replay will be accessible via the company’s “For Investors” page on its website.

Key Terms

fgfr

1 terms

fgfr technical

"Fibroblast Growth Factor Receptor (FGFR) biology"

FGFR (fibroblast growth factor receptor) is a family of cell-surface proteins that bind growth factors and send signals telling cells to grow, divide, or move. Mutations or abnormal activity in FGFRs can drive certain cancers or other diseases, making them common targets for drugs and diagnostic tests. For investors, FGFR status matters because it can determine whether a drug candidate targets a clear biological mechanism, affects clinical trial design, or supports companion diagnostics and market opportunity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARLSBAD, Calif., Sept. 8, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conference:

Cantor Global Healthcare Conference 2026
Format: Virtual fireside chat and one-on-one investor meetings
Presentation Date/Time: Wednesday, September 9, 2026 at 1:00 PM ET
Location: New York, NY

A live webcast of the presentation can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.

About Tyra Biosciences

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help TYRA design and predict which candidates may demonstrate the highest potency, selectivity and tolerability in the clinic. TYRA's expertise in FGFR biology has created a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. TYRA's lead precision medicine stemming from SNÅP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for low-grade upper tract urothelial carcinoma, low-grade intermediate-risk non-muscle invasive bladder cancer and achondroplasia. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma. TYRA is based in Carlsbad, California.

For more information, please visit www.tyra.bio and engage with TYRA on LinkedIn.

Contact
Amy Conrad
aconrad@tyra.bio

View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-present-at-the-cantor-global-healthcare-conference-302872416.html

SOURCE Tyra Biosciences

FAQ

How can investors access Tyra Biosciences’ presentation and replay from the Cantor Global Healthcare Conference 2026?

A live webcast of Tyra Biosciences’ presentation can be accessed by visiting the “For Investors” page on the company’s website, where a replay will also be available following the event.